



Final Appraisal Recommendation

Advice number: 1922 – October 2022

Ferric maltol (Feraccru®) 30 mg hard capsules

Resubmission by Norgine Pharmaceuticals Ltd

Recommendation of the All Wales Medicines Strategy Group

Ferric maltol (Feraccru®) is recommended as an option for restricted use within NHS Wales.

Ferric maltol (Feraccru®) is licensed for the treatment of iron deficiency in adults.

Ferric maltol (Feraccru®) is restricted for use in adult patients with inflammatory bowel disease (IBD) who have mild to moderate iron deficiency anaemia (IDA) and have failed on, or are intolerant to, standard oral iron products and are considered suitable for intravenous iron.

Ferric maltol (Feraccru®) is not recommended for use within NHS Wales outside of this subpopulation.

Additional note(s):

- AWMSG took into account the British Society of Gastroenterology (BSG) guidelines for the management of iron deficiency anaemia in adults.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 5116), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation –
1922:

Ferric maltol (Feraccru®) 30 mg hard capsules. October 2022.